書籍詳細

心臓【心不全】

P.13 掲載の参考文献

• 1) Pfeffer MA, Swedberg K, Granger CB et al, CHARM Investigators and Committees:Effects of candesartan on mortality and morbidity in patients with chronic heart failure:the CHARM-Overall programme. Lancet 362:759-766, 2003
  pubmed

• 2) Granger CB, McMurray JJ, Yusuf S et al, CHARM Investigators and Committees:Effects of can-desartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors:the CHARM-Alternative trial. Lancet 362:772-776, 2003
  pubmed

• 3) McMurray JJ, Ostergren J, Swedberg K et al, CHARM Investigators and Committees:Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors:the CHARM-Added trial. Lancet 362:767-771, 2003
  pubmed

• 4) Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators:A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667-1675, 2001

• 5) Yusuf S, Pfeffer MA, Swedberg K et al;CHARM Investigators and Committees:Effects of can-desartan in patients with chronic heart failure and preserved left-ventricular ejection fraction:the CHARM-Preserved Trial. Lancet 362:777-781, 2003
  pubmed

P.15 掲載の参考文献

• 1) The COMET Investigators:Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET):randomised controlled trial. Lancet 362:7-13, 2003

• 2) The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group:Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342:1441-1446, 1993

• 3) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999

P.16 掲載の参考文献

• 1) Packer M, Coats AJ, Fowler MB et al:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001
  pubmed

P.18 掲載の参考文献

• 1) Pitt B, Remme W, Zannad F et al:Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321, 2003
  pubmed

P.21 掲載の参考文献

• 1) Echt DS, Liebson PR, Mitchell LB et al:Mortality and morbidity in patients receiving encainide, flecainide, or placebo:the Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781-788, 1991

• 2) Doval HC, Nul DR, Grancelli HO et al:Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 344:493-498, 1994
  pubmed

P.23 掲載の参考文献

• 1) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999

• 2) Gottlieb SS, Fisher ML, Kjekshus J et al:Toler-ability of β-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation 105:1182-1188, 2002

• 3) Wikstrand J, Hjalmarson A, Waagstein F et al:Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure. J Am Co Cardiol 40:491-498, 2002
  pubmed

• 4) Hjalmarson A, Goldstein S, Fagerberg B et al:Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. JAMA 283:1295-1302, 2000
  pubmed

P.25 掲載の参考文献

• 1) Abraham WT, Fisher WG, Smith AL et al, MIRACLE Study Group:Multicenter InSync Randomized Clinical Evaluation:Cardiac resynchronization in chronic heart failure. N Engl J Med 346:1845-1853, 2002

• 2) Gregoratos G, Abrams J, Epstein AE et al:ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines:ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices:summary article:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 106:2145-2161, 2002

P.27 掲載の参考文献

• 1) Cazeau S, Leclercq C, Lavergne T et al:Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344:873-880, 2001

• 2) Leclercq C, Walker S, Linde C et al:Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 23:1780-1787, 2002
  pubmed

• 3) Linde C, Leclercq C, Rex S et al:Long-term benefits of biventricular pacing in congestive heart failure:Results from the multisite stimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 40:111-118, 2002
  pubmed

P.29 掲載の参考文献

• 1) Cuffe MS, Califf RM, Adams KF Jr et al:Shortterm intravenous milrinone for acute exacerbation of chronic heart failure:a randomized controlled trial. JAMA 287:1541-1547, 2002
  pubmed

P.31 掲載の参考文献

• 1) Nanas JN, Alexopoulos G, Anastasiou-Nana MI et al:Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril:a multicenter study. J Am Coll Cardiol 36:2090-2095, 2000
  pubmed

• 2) The CONSENSUS Trial Study Group:Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scan-dinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429-1435, 1987

• 3) The SOLVD Investigators:Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302, 1991
  pubmed

• 4) Cohn JN, Johnson G, Ziesche S et al:A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303-310, 1991
  pubmed

• 5) Packer M, Poole-Wilson PA, Armstrong PW et al:Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100:2312-2318, 1999

• 6) The NETWORK Investigators:Clinical outcome with enalapril in symptomatic chronic heart failure;a dose comparison. Eur Heart J 19:481-489, 1998

P.33 掲載の参考文献

• 1) Packer M, Califf RM, Konstam MA et al:Comparison of omapatrilat and enalapril in patients with chronic heart failure:the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106:920-926, 2002
  pubmed

P.35 掲載の参考文献

• 1) Kaluski E, Kobrin I, Zimlichman R et al:RITZ-5:randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema:a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 41:204-210, 2003

• 2) Yanagisawa M, Kurihara H, Kimura S et al:A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415, 1988
  pubmed

P.37 掲載の参考文献

• 1) Cohn JN, Tognoni G:A randomized trial of the anigiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667-1675, 2001

P.39 掲載の参考文献

• 1) Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF):Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure:a randomized controlled trial. JAMA 287:1531-1540, 2002
  pubmed

• 2) Colucci WS, Elkayam U, Horton DP et al:Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 343:246-253, 2000

P.41 掲載の参考文献

• 1) The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators:A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825-1833, 2002

P.43 掲載の参考文献

• 1) Weerasooriya R, Davis M, Powell A et al:The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol 41:1697-1702, 2003
  pubmed

• 2) Kay GN, Ellenbogen KA, Giudici M et al:The Ablate and Pace Trial:a prospective study of catheter ablation of the AV conduction system and permanent pacemaker inplantation for treatment of atrial fibrillation. J Interv Card Electrophysiol 2:121-135, 1998

P.45 掲載の参考文献

• 1) Strickberger SA, Hummel JD, Bartlett TG et al:Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol 41:1707-1712, 2003
  pubmed

P.47 掲載の参考文献

• 1) Kuck KH, Cappato R, Siebels J et al:Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study Hamburg (CASH). Circulation 102:748-754, 2000
  pubmed

P.49 掲載の参考文献

• 1) Singh SN, Fletcher RD, Fisher SG et al:Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 333:77-82, 1995
  pubmed

• 2) Hammill SC, Packer DL:Amiodarone in congestive heart failure:unravelling the GESICA and CHF-STAT differences. Heat 75:6-7, 1996

P.51 掲載の参考文献

• 1) Connolly SJ, Gent M, Roberts RS et al:Canadian implantable defibrillator study (CIDS):a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101:1297-1302, 2000
  pubmed

P.53 掲載の参考文献

• 1) Roy D, Talajic M, Dorian P et al:Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 342:913-920, 2000
  pubmed

• 2) AFFIRM Investigators:Acomparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825-1833, 2002

P.55 掲載の参考文献

• 1) Connolly SJ, Kerr CR, Gent M et al:Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. N Engl J Med 342:1385-1391, 2000

• 2) Skanes AC, Krahn AD, Yee R et al:Progression to chronic atrial fibrillation after pacing:the Canadian Trial of Physiologic Pacing. J Am Coll Cardiol 38:167-172, 2001
  pubmed

P.57 掲載の参考文献

• 1) Gregoratos G, Abrams J, Epstein AE et al:ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices:summary article:a report of the ACC/AHA Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines) . Circulation 106:2145-2161, 2002
  pubmed

• 2) Wilkoff BL:Should all patients receive dual chamber pacing ICDs? The rationale for the DAVID trial. Curr Control Trials Cardiovasc Med 2:215-217, 2001
  pubmed

P.59 掲載の参考文献

• 1) Moss AJ, Hall WJ, Cannom DS et al:Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 335:1933-1940, 1996

• 2) Moss AJ, Zareba W, Hall WJ et al:Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl/Med 346:877-883, 2002
  pubmed

P.61 掲載の参考文献

• 1) Abraham WT, Fisher WG, Smith AL et al, MIRACLE Study Group:Multicenter InSync Randomized Clinical Evaluation:Cardiac resynchronization in chronic heart failure. N Engl J Med 346:1845-1853, 2002

P.64 掲載の参考文献

• 1) Abraham WT, Fisher WG, Smith AL et al:MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation:Cardiac resynchronization in chronic heart failure. N Engl J Med 346:1845-1853, 2002

• 2) Young JB, Abraham WT, Smith AL et al:Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure:the MIRACLE ICD Trial. JAMA 289:2685-2694, 2003
  pubmed

P.67 掲載の参考文献

• 1) Buxton AE, Lee KL, Fisher JD et al:A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 341:1882-1890, 1999
  pubmed

P.69 掲載の参考文献

• 1) Hohnloser SH, Kuck KH, Lilienthal J for the PIAF investigators:Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF):a randomised trial. Lancet 356:1789-1794, 2000

P.71 掲載の参考文献

• 1) Van Gelder IC, Hagens VE, Bosker HA et al for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group (RACE):A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834-1840, 2002

P.73 掲載の参考文献

• 1) Montalescot G, Barragan P, Wittenberg O et al, ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up:Platelet glycoprotein II b/III a inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344:1895-1903, 2001

P.76 掲載の参考文献

• 1) Batchelor WB, Mahaffey KW, Berger PB et al:A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting:the ATLAST trial. J Am Coll Cardiol 38:1608-1613, 2001

• 2) The EPISTENT Investigators:Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352:87-92, 1998
  pubmed

• 3) The EPIC Investigators:Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956-961, 1994
  pubmed

• 4) The EPILOG Investigators:Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689-1696, 1997
  pubmed

• 5) The CAPTURE Investigators:Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina:the CAPTURE Study[erratum published Lancet 359:744, 1997].Lancet 349:1429-1435, 1997

• 6) The IMPACT-II Investigators:Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention:IMPACT-II. Lancet 349:1422-1428, 1997
  pubmed

P.79 掲載の参考文献

• 1) Cercek B, Shah PK, Noc M et al:Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial:arandomised controlled trial. Lancet 361:809-813, 2003
  pubmed

• 2) Gurfinkel E, Bozovich G, Beck E et al:Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study. Eur Heart J 20:121-127 1999
  pubmed

• 3) Muhlestein JB, Anderson JL, Carlquist JF et al:Randomized secondary prevention trial of azithromycin in patients with coronary artery disease:primary clinical results of the ACADEMIC study. Circulation 102:1755-1760, 2000
  pubmed

P.81 掲載の参考文献

• 1) The CAPRICORN Investigators:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
  pubmed

P.83 掲載の参考文献

• 1) CAPTURE Investigators:Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable an-gina:the CAPTURE Study. Lancet 349:1429-1435, 1997

• 2) Hamm CW, Heeschen C, Goldmann B et al:Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c 7 E 3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 340:1623-1629, 1999, Erratum in:N Engl Med 341:548, 1999

P.85 掲載の参考文献

• 1) Lincoff AM, Califf RM, Moliterno DJ et al:Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med 341:319-327, 1999
  pubmed

• 2) The PURSUIT Trial Investigators:Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 339:436-443, 1998
  pubmed

• 3) The PRISM-PLUS Study Investigators:Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction[published correction appears in N Engl J Med 339:415, 1998]. N Engl J Med 338:1488-1497, 1998

• 4) The RESTORE Investigators:Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 96:1445-1453, 1997
  pubmed

• 5) Batchelor WB, Tolleson TR, Huang Y et al:Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes:The COMPARE trial. Circulation 106:1470-1476, 2002
  pubmed

P.87 掲載の参考文献

• 1) Bhatt DL, Lee BI, Casterella PJ et al:Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention:results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol 41:20-25, 2003
  pubmed

• 2) The GUSTO Investigators:An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673-682, 1993
  pubmed

• 3) Rao AK, Pratt C, Berke A et al:Thrombolysis in Myocardial Infarction (TIMI) trial-phase I:hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11:1-11, 1988
  pubmed

P.88 掲載の参考文献

• 1) Budaj A, Yusuf S, Mehta SR et al:Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 106:1622-1626, 2002
  pubmed

• 2) Antman EM, Cohen M, Bernink PJ et al:The TIMI risk score for unstable angina/non-ST elevation MI:A method for prognostication and therapeutic decision making. JAMA 284:835-842, 2000

• 3) The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (CURE):Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502, 2001

• 4) Mehta SR, Yusuf S, Peters RJ et al:Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:the PCI-CURE study. Lancet 358:527-533, 2001
  pubmed

P.92 掲載の参考文献

• 1) Kober L, Bloch Thomsen PE, Molleer M et al:Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction:a randomised trial. Lancet 356:2052-2058, 2000

• 2) Echt DS, Liebson PR, Mitchell B et al and CAST investigators:Mortality and morbidity in patients receiving encainide, flecainaide, or placebo:The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781-788, 1991

P.95 掲載の参考文献

• 1) Antman EM, Louwerenburg HW, Baars HF et al:Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction:results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 105:1642-1649, 2002
  pubmed

• 2) Topol EJ, GUSTO V Investigators:Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition:the GUSTO-V randomised trial. Lancet 357:1905-1914, 2001

• 3) Antman EM, Giugliano RP, Gibson CM et al:Abciximab facilitates the rate and extent of thrombolysis:results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 99:2720-2732, 1999
  pubmed

P.97 掲載の参考文献

• 1) Zeymer U, Suryapanata H, Monassier JP et al:Evaluation of the safety and of the cardioprotective effects of eniporide, a specific sodium/hydrogen exchange inhibitor given as adjunctive therapy to reperfusion in patients with acute myocardial infarction:rationalc, design and protocol of the ESCAMI study. Heart study. 1:71-76, 2001

• 2) Zeymer U, Suryapranata H, Monassier JP et al:The Na+/H+Exchange Inhibitor Eniporide as an Adjunct to Early Reperfusion Therapy for Acute Myocardial Infarction. J Am Coll Cardiol 38:1644-1650, 2001

P.98 掲載の参考文献

• 1) O'Shea JC, Buller CE, Cantor WJ et al:Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 287:618-621, 2002
  pubmed

• 2) The ESPRIT Investigators:Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT):arandomized, placebo-controlled trial. Lancet 356:2037-2044, 2000

• 3) Topol EJ, Mark DB, Lincoff AM et al for the EPISTENT Investigators:Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting:results from a multicentre randomised trial. Lancet 354:2019-2024, 1999
  pubmed

P.100 掲載の参考文献

• 1) Goodman SG, Cohen M, Bigonzi F et al:Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease. J Am Coll Cardiol 36:693-698, 2000
  pubmed

• 2) Cohen M, Demers C, Gurfinkel EP et al:Acomparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 337:447-452, 1997

• 3) Oler A, Whooley MA, Oler J et al:Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 276:811-815, 1996
  pubmed

P.104 掲載の参考文献

• 1) Moscucci M, Fox KA, Cannon CP et al:Predictors of major bleeding in acute coronary syndromes:the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24:1815-1823, 2003
  pubmed

• 2) Montalescot G, Van de Werf F, Gulba DC et al:Stenting and glycoprotein IIb/IIIa inhibition inpatients with acute myocardial infarction undergoing Percutaneous coronary intervention:findings from the global registry of acute coronary events (GRACE). Catheter Cardiovasc Interv 60:360-367, 2003

• 3) Fox KA, Goodman SG, Klein W et al:Management of acute coronary syndromes. Variations in practice and outcome;findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 23:1177-1189, 2002
  pubmed

• 4) Eagle KA, Goodman SG, Avezum A et al:Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction:findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 359:373-377, 2002

• 5) Spencer FA, Santopinto JJ, Gone JM et al:Impact of aspirin on presentation and hospital outcomes in patients with acute coronary syndromes (The Global Registry of Acute Coronary Events [GRACE]).Am J Cardiol 90:1056-1061, 2002

• 6) Santopinto JJ, Fox KA, Goldberg RJ et al:Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes:findings from the global registry of acute coronary events (GRACE). Heart 89:1003-1008, 2003
  pubmed

• 7) Klein W, Kraxner W, Hodl R et al:Patterns of use of heparins in ACS. Correlates and hospital out-comes:the Global Registry of Acute Coronary Events (GRACE). Thromb Haemost 90:519-527, 2003

• 8) Steg PG, Goldberg RJ, Gore JM et al:Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 90:358-363, 2002

• 9) GRACE Investigators:Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project:a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 141:190-199, 2001

P.108 掲載の参考文献

• 1) Simoons ML, GUSTO IV-ACS Investigators:Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet 357:1915-1924, 2001
  pubmed

• 2) Cohen M:Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes:Gusto IV-ACS. Lancet 357:1899-1900, 2001
  pubmed

• 3) Ottervanger JP, Armstrong P, Barnathan ES et al, GUSTO IV-ACS Investigators:Long-term results after the glycoprotein II b/III a inhibitor abciximab in unstable angina:one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV-Acute Coronary Syndrome) Trial. Circulation 107:437-442, 2003

• 4) EPIC Investigators:Use of a monoclonal antibody directed against the platelet glycoprotein II b/III a receptor in high-risk coronary angioplasty. N Engl J Med 330:956-961, 1994

• 5) EPILOG Investigators:Platelet glycoprotein II b/ III a receptor blockade and low-dose heparin during Percutaneous coronary revascularization. N Engl J Med 336:1689-1696, 1997

P.111 掲載の参考文献

• 1) Lincoff AM, Califf RM, Van de Werf F et al:Global Use of Strategies To Open Coronary Arteries Investigators (GUSTO):Mortality at 1 year with combination platelet glycoprotein II b/III ainhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction:GUSTO V randomized trial. JAMA 288:2130-2135, 2002

• 2) Topol EJ, GUSTO V Investigators Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition:the GUSTO V randomised trial. Lancet 357:1905-1914, 2001

P.113 掲載の参考文献

• 1) Ross AM, Molhoek P, Lundergan C et al:Randomized Comparison of Enoxaparin, a Low-Molecular-Weight Heparin, With Unfractionated Heparin Adjunctive to Recombinant Tissue Plasminogen Activator Thrombolysis and Aspirin:Second Trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 104:648-652, 2001
  pubmed

P.114 掲載の参考文献

• 1) Goodman SG, Fitchett D, Armstrong PW et al:Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glyco-protein IIb/IIIa inhibitor eptifibatide. Circulation 107:238-244, 2003

• 2) Cohen M, Demers C, Gurfinkel EP et al:Acomparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 337:447-452, 1997

P.117 掲載の参考文献

• 1) Brener SJ, Zeymer U, Adgey AAJ et al:Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction. J Am Coll Cardiol 39:377-386, 2002
  pubmed

• 2) Ohman EM, Kleiman NS, Gacioch G et al:Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 95:846-854, 1997
  pubmed

P.119 掲載の参考文献

• 1) Schwartz GG, Olsson AG, Ezekowitz MD et al:Effects of Atorvastatin on early recurrent ischemic events in acute coronary syndromes:the MIRACL study:a randomized controlled trial. JAMA 285:1711-1718, 2001
  pubmed

P.121 掲載の参考文献

• 1) Eikelboom JW, Anand SS, Mehta SR et al:Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation:Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) study. Circulation 103:643-650, 2001
  pubmed

• 2) Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators:Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation:a randomized trial. Lancet 353:429-438, 1999
  pubmed

P.123 掲載の参考文献

• 1) Dickstein K, Kjekshus J:Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction:the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 83:477-481, 1999
  pubmed

• 2) Dickstein K, Kjekshus J, OPTIMAAL Trial Steering Committee and Investigators:Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan:Comparison of baseline data, initial course, and management:losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 87:766-771, A7, 2001

• 3) Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group:Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction:the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360:752-760, 2002

P.125 掲載の参考文献

• 1) Weaver WD, Reisman MA, Griffin JJ et al:Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1):a randomised trial. Lancet 355:2199-2203, 2000
  pubmed

• 2) The F. R. O. S. T. Study Group:The French Randomised Optimal Stenting Trial:a prospective evaluation of provisional stenting guided by coronary velocity reserve and quantitative coronary angiography. J Am Coll Cardol 36:404-409, 2000

P.127 掲載の参考文献

• 1) Cannon CP, McCabe CH, Wilcox RG et al for the OPUS-TIMI 16 Investigators:Oral glycoprotein II b/III a inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) Trial. Circulation 102:149-156, 2000

• 2) EPIC Investigators:Use of a monoclonal antibody directed against the platelet glycoprotein II b/III a receptor in high-risk coronary angioplasty. N Engl J Med 330:956-961, 1994

• 3) EPILOG Investigators:Platelet glycoprotein II b/ III a receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689-1696, 1997

P.129 掲載の参考文献

• 1) Moliterno DJ, for the PARAGON B International Steering Committee:Patient-specific dosing of IIb/ III a antagonists during acute coronary syndromes:rationale and design of the PARAGON B study. Am Heart J 139:563-566, 2000

• 2) The Platelet II b/III a Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network (PARAGON)-B Investigators:Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation 105:316-321, 2002

• 3) Boersma E, Harrington RA, Moliterno DJ et al:Platelet glycoprotein II b/III a inhibitors in acute coronary syndromes:a meta-analysis of all major randomized clinical trials. Lancet 359:189-198, 2002

P.131 掲載の参考文献

• 1) Coussement PK, Bassand JP, Convens C et al:A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction:The PENTALYSE study. Eur Heart J 22:1716-1724, 2001
  pubmed

• 2) Vuillemenot A, Schiele F, Meneveau N et al:Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent a pilot study in the setting of coronary angioplasty. Thromb Heamost 81:214-220, 1999
  pubmed

• 3) Ross AM, Molhoek P, Lundergan C et al:Randomized comparison of enoxaparin, a low-molecular weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin:second trial of Heparin and Aspirin Reperfusion Therapy (HART II) . Circulation 104:648-652, 2001
  pubmed

P.135 掲載の参考文献

• 1) Widimsk'y P, Groch L, Zelizko M et al:Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE Study. Euar Heart J 21:823-831, 2000

• 2) Krupicka J, Widimsky P, Nechvatal L et al:Inter-hospital transport for primary angioplasty does not compromise left ventricular function:Six-month echocardiographic follow-up of the PRAGUE 1 study. Jpn Heart J 44:313-322, 2003

• 3) Widimsky P, Budesinsky T, Vorac D et al:Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial-PRAGUE-2. Eur Heart J 24:94-104, 2003
  pubmed

P.136 掲載の参考文献

• 1) Luepker RV, Raczynski JM, Osganian S et al:Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease:The Rapid Early Action for Coronary Treatment (REACT) Trial. JAMA 284:60-67, 2000
  pubmed

• 2) Brodie BR, Stuckey TD, Wall TC et al:Importance of time to reperfusion for 30-days and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 32:1312-1319, 1998

• 3) Raczynski JM, Finnegan JR, Zapka JG et al:REACT theory-based intervention to reduce treatment-seeking delay for acute MI. Am J Prev Med 16:325-334, 1999

• 4) Goff DC Jr, Sellers DE, McGovern PG et al:Knowledge of heart attacks symptoms in a population survey in the United States:The REACT Trial. Arch Intern Med 158:2329-2338, 1998

P.140 掲載の参考文献

• 1) Fox KA, Poole-Wilson PA, Henderson RA et al, for the Randomized Intervention Trial of unstable angina (RITA) investigators:Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction;the British Heart Foundation RITA 3 randomised trial. Lancet 360:743-751, 2002

P.143 掲載の参考文献

• 1) Gibler WB, Hoekstra JW, Weaver WD et al:A randomized trial of the effects of early cardiac serum marker availability on reperfusion therapy in patients with acute myocardial infarction:the serial markers, acute myocardial infarction and rapid treatment trial (SMARTT). J Am Coll Cardiol 36:1500-1506, 2000

P.145 掲載の参考文献

• 1) Stone AF, Mendall MA, Kaski JC et al:Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes:South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 106:1219-1223, 2002

P.147 掲載の参考文献

• 1) Le May MR, Labinaz M, Davies RF et al:Stenting versus thrombolysis in acute myocardial infarction trial (STAT).J Am Coll Cardiol 37:985-991, 2001
  pubmed

• 2) The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators:A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 336:1621-1628, 1997

P.149 掲載の参考文献

• 1) Grines CL, Cox DA, Stone GW et al:Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 341:1949-1956, 1999

P.150 掲載の参考文献

• 1) Schomig A, Kastrati A, Dirschinger J et al:Coronay stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 343:385-391, 2000

• 2) Gibbons RJ, Holmes DR, Reeder GS et al:Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 328:685-691, 1993
  pubmed

• 3) Lincoff AM, Califf RM, Moliterno DJ et al:Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med 341:319-327, 1999
  pubmed

P.153 掲載の参考文献

• 1) Kastrati A, Mehilli J, Dirschinger J et al:Myocardial salvage after coronary stenting plus abciximabversus fibrinolysis plus abciximab in patients with acute myocardial infarction:a randomised trial. Lancet 359:920-925, 2002
  pubmed

• 2) Schomig A, Kastrati A, Dirschinger J et al:Coronay stenting Plus Platelet glycoprotein II b/IIIa blockade compared with tissue plasminogen activatior in acute myocardial infarction. N Engl J Med 343:385-391, 2000

• 3) Antman EM, Giugliano RP, Gibson CM et al:Abciximab facilitates the rate and extent of thrombolysis:results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 99:2720-2732, 1999
  pubmed

P.155 掲載の参考文献

• 1) The SYMPHONY Investigators:Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes:a randomized trial. Lancet 355:337-345, 2000
  pubmed

P.158 掲載の参考文献

• 1) Cannon CP, Weintraub WS, Demopoulos LA et al, for the TACTICS-thrombolysis in myocardial infarction 18 investigators:Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344:1879-1887, 2001
  pubmed

• 2) Morrow DA, Cannon CP, Rifai N et al:Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction:results from a randomized trial. JAMA 286:2405-2412, 2001

• 3) Sabatine MS, Morrow DA, de Lemos JA et al:Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes:simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circualation 105:1760-1763, 2002

• 4) Wong GC, Morrow DA, Murphy S et al:Elevations in troponin T and I are associated with abnormal tissue level perfusion:a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation 106:202-207, 2002
  pubmed

• 5) de Lemos JA, Morrow DA, Gibson CM et al:The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11 B and TACTICS-TIMI 18 studies. J Am Coll Cardiol 40:238-244, 2002

• 6) Kleiman NS, Lakkis N, Cannon CP et al:Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol 40:1044-50, 2002
  pubmed

• 7) Mahoney EM, Jurkovitz CT, Chu et al:Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 288:1851-1858, 2002
  pubmed

• 8) Glaser R, Herrmann HC, Murphy SA et al:Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA 288:3124-3129, 2002
  pubmed

• 9) Morrow DA, de Lemos JA, Sabatine MS et al:Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction:B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Collcardiol 41:1264-1272, 2003
  pubmed

P.161 掲載の参考文献

• 1) Topol EJ, Moliterno DJ, Herrmann HC et al:Comparison of two platelet glycoprotein II b/III a inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344:1888-1894, 2001

• 2) Moliterno DJ, Topol EJ for the TARGET International Steering Committee:A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement:rationale and design of the TARGET study. Am Heart J 140:722-726, 2000

P.163 掲載の参考文献

• 1) Pedersen OD, Bagger H, Kober L et al:Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100:376-380, 1999
  pubmed

• 2) The TRACE Study Group:The Trandolapril Cardiac Evaluation (TRACE) Study:rationale, design, and baseline characteristics of the screened population. Am J Cardiol 73:44 C-50 C, 1994

• 3) Kober L, Trop-Pedersen C:Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study. A J Cardiol 76:1-5, 1995

• 4) Torp-Pedersen C, Kober L:Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Lancet 354:9-12, 1999
  pubmed

P.165 掲載の参考文献

• 1) Pfeffer MA, McMurray JJV, Velazquez EJ et al:Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893-1906, 2003

• 2) Pfeffer MA, Braunwald E, Moye LA et al:Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl Med 327:669-677, 1992
  pubmed

• 3) The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators:Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821-828, 1993

• 4) Kober L, Torp-Pedersen C, Carlsen JE et al:A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333:1670-1676, 1995
  pubmed

• 5) Dickstein K, Kjekshus J for the OPTIMAAL Study Group:Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction:the OPTIMAAL randomised trial.Lancet 360:752-760, 2002

• 6) Dahlof B, Devereux RB, Kieldsen SE et al for the LIFE study group:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002

• 7) Brenner BM, Cooper ME, de Zeeuw D et al for the RENAAL Study Investigators:Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001

P.167 掲載の参考文献

• 1) Serruys PW, Foley DP, Suttorp MJ et al:A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions:final results of the additional value of NIR stents for treatment of long coronary lesions (ADVANCE) study. J Am Coll Cardiol 39:393-399, 2002
  pubmed

• 2) Colombo A, De Gregorio J, Moussa I et al:Intravascular ultrasound-guided percutaneous transluminal coronary angiography with provisional spot stenting for treatment of long coronary lesions. J Am Coll Cardiol 38:1427-1433, 2001
  pubmed

• 3) Schofer J, Schluter M, Gershlick AH et al:Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries:double-blind, randomised controlled trial (E-SIRIUS). Lancet 362:1093-1099, 2003
  pubmed

P.169 掲載の参考文献

• 1) Serruys PW, Unger F, Sousa JE et al for the Arterial Revascularization Therapies Study Group:Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344:1117-1124, 2001

• 2) Abizaid A, Costa MA, Centemero M et al:Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients:insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 104:533-538, 2001
  pubmed

• 3) Costa MA, Carere RG, Lichtenstein SV et al:Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the arterial revascularization therapies study (ARTS). Circulation 104:2689-2693, 2001
  pubmed

• 4) van den Brand MJ, Rensing BJ, Morel MA et al:The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol 39:559-564, 2002

P.171 掲載の参考文献

• 1) Park SJ, Shim WH, Ho DS et al:Apaclitaxel-eluting stent for the prevention of coronary res-tenosis. N Engl J Med 348:1537-1545, 2003

• 2) Colombo A, Drzewiecki J, Banning A et al:Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108:788-794, 2003
  pubmed

• 3) Morice MC, Serruys PW, Sousa JE et al:A radomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773-1780, 2002

P.172 掲載の参考文献

• 1) Morrison DA, Sethi G, Sacks J et al:Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia:AWESOME randomized trial and registry experience with post-CABG patients. J Am Coll Cardiol 40:1951-1954, 2002
  pubmed

• 2) Eagle KA, Guyton RA, Davidoff R et al:ACC/ AHA guidelines for coronary artery bypass graft surgery:a report of the American College of Cardiology/American Heart Association task force on Practice Guidelines (Committee to revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol 34:1262-1347, 1999

P.175 掲載の参考文献

• 1) Schiele F, Meneveau N, Gilard M et al:Intravascular ultrasound-guided balloon angioplasty compared with stent:immediate and 6-month results of the multicenter, randomized Balloon Equivalent to Stent Study (BEST). Circulation 107:545-551, 2003
  pubmed

P.177 掲載の参考文献

• 1) Carrie D, Khalife K, Citron B et al:Comparison of direct coronary stenting with and without balloon predilatation in patients with stable angina pectoris. Am J Cardiol 87:693-698, 2001
  pubmed

• 2) Loubeyre C, Morice MC, Lefevre T et al:A randomised comparison of direct stenting with conventional stent implantation in selected patients With Acute Myocardial Infarction. J Am Coll Cardol 39:15-21, 2002

P.179 掲載の参考文献

• 1) Angelini GD, Taylor FC, Reeves BC et al:Early and midterm outcome after off-pump and on-pump surgery in Beating Heart Against Cardioplegic Arrest Studies (BHACAS 1 and 2):a pooled analysis of two randomised controlled trials. Lancet 359:1194-1199, 2002
  pubmed

• 2) Ascione R, Caputo M, Calori G et al:Predictors of atrial fibrillation after conventional and beating heart coronary surgery:aprospective, randomised study. Circulation 102:1530-1535, 2000

• 3) Ascione R, Lloyd CT, Underwood MJ et al:Economic outcome of off-pump coronary artery bypass surgery:a prospective randomized study. Ann Thorac Surg 68:2237-2242, 1999
  pubmed

• 4) van Dijk D, Nierich AP, Jansen EW et al:Early outcome after off-pump versus on-pump coronary bypass surgery:results from a randomized study. Circulation 104:1761-1766, 2001
  pubmed

P.181 掲載の参考文献

• 1) Jorgensen B, Simonsen S, Endresen K et al:Restenosis and clinical outcome in patients treated with amlodipine after angioplasty:results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 35:592-599, 2000
  pubmed

• 2) Pitt B, Byington RP, Furberg CD et al:Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 102:1503-1510, 2000
  pubmed

P.183 掲載の参考文献

• 1) Bertrand ME, Rupprecht HJ, Urban P et al:Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting:the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102:624-629, 2000
  pubmed

P.185 掲載の参考文献

• 1) Poldermans D, Boersma E, Bax JJ et al:The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Engl J Med 341:1789-1794, 1999

• 2) Boersma E, Poldermans D, Bax JJ et al:Predictors of cardiac events after major vascular surgery. Role of clinical characteristics, dobutamine echocardiography, and β-blocker therapy. JAMA 285:1865-1873, 2001

P.187 掲載の参考文献

• 1) The EPILOG investigators:Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Eng J Med 336:1689-1696, 1997

• 2) Lincoff AM, Tcheng JE, Califf RM et al:Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. One-year outcome in the EPILOG trial. Circulation 99:1951-1958, 1999
  pubmed

• 3) The EPIC investigators:Use of a monoclonal antibody directed against the platelet glycoprotein IIb/ IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956-961, 1994
  pubmed

P.189 掲載の参考文献

• 1) Stone G, Rogers C, Hermiller J et al:Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 108:548-553, 2003

P.191 掲載の参考文献

• 1) Leon MB, Teirstein PS, Moses JW et al:Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 344:250-256, 2001
  pubmed

• 2) Waksman R, Ajani AE, Pinnow E et al:Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma radiation therapy for in-stent restenosis:Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation 106:776-778, 2002
  pubmed

P.193 掲載の参考文献

• 1) Neumann F, Kastrati A, Miethke T et al:Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3):arandomised, double-blind, placebo-controlled trial [comment]. Lancet 357:2085-2089, 2001
  pubmed

P.195 掲載の参考文献

• 1) Kastrati A, Schomig A, Dirschinger J et al:A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. Circulation 102:2593-2598, 2000
  pubmed

• 2) Koning R, Eltchaninoff H, Commeau P et al:Stent placement compared with balloon angioplasty for small coronary arteries:in-hospital and 6-month clinical and angiographic results. Circulation 104:1604-1608, 2001
  pubmed

• 3) Moer R, Myreng Y, Molstad P et al:Stenting in small coronary arteries (SISCA) trial. A randomized comparison between balloon angioplasty and the heparin-coated beStent. J Am Coll Cardiol 38:1598-1603, 2001

P.197 掲載の参考文献

• 1) Kastrati A, Mehilli J, Dirschinger J et al:Intracoronary stenting and angiographic results:strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 103:2816-2821, 2001
  pubmed

• 2) Hausleiter J, Kastrati A, Mehilli J et al:Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. J Am Coll Cardiol 40:882-889, 2002
  pubmed

P.199 掲載の参考文献

• 1) Shaw LW:Effects of a prescribed supervised exercise program on mortality and cardiovascular morbidity in patients after a myocardial infarction. The National Exercise and Heart Disease Project. Am J Cardiol 48:39-46, 1981
  pubmed

• 2) Dorn J, Naughton J, Imamura D et al:Results of a multicenter randomized clinical trial of exercise and long-term survival in myocardial infarction patients:the National Exercise and Heart Disease Project (NEHDP). Circulation 100:1764-1769, 1999

• 3) Oldridge NB, Guyatt GH, Fischer ME et al:Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA 260:945-950, 1988
  pubmed

P.201 掲載の参考文献

• 1) Borst C, Jansen EW, Tulleken CA et al:Coronary artery bypass grafting without cardiopulmonary bypass and without interruption of native coronary flow using a novel anastomosis site restraining device ("Octopus"). J Am Coll Cardio l 27:1356-1364, 1996

• 2) Nathoe HM, van Dijk D, Jansen EW et al:A comparison of On-pump and Off-pump coronary bypass surgery in low-risk patients. N Engl J Med 348:394-402, 2003

• 3) Cleveland JC Jr, Shroyer AL, Chen AY et al:Off-pump coronary artery bypass grafting decreases risk-adjusted mortality and morbidity. Ann Thorac Surg 72:1282-1288, 2001
  pubmed

P.202 掲載の参考文献

• 1) Mudra H, di Mario C, de Jaegere P et al:Randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS Study). Circulation 104:1343-1349, 2001
  pubmed

• 2) de Jaegere P, Mudra H, Figulla H et al:Intravascular ultrasound-guided optimized stent deployment:Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J 19:1214-1223, 1998

P.204 掲載の参考文献

• 1) Holmes DR, Savage M, LaBlanche JM et al:Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial. Curculation 106:1243-1250, 2002

• 2) Tamai H, Katoh O, Suzuki T et al:Impact of tranilast on restenosis after coronary angioplasty:Tranilast Restenosis Following Angioplasty Trial (TREAT). Am Heart J 138:968-975, 1999
  pubmed

• 3) Tamai H, for the TREAT Group:Inhibitory effect of tranilast on restenosis after percutaneous transluminal coronary angioplasty (PTCA):a phase III multicenter randomized double blind placebocontrolled trial. J Clin Ther Med 12:65-85, 1996

P.207 掲載の参考文献

• 1) Byington RP, Miller ME, Herrington D et al:Rationale, design and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Traial (PREVENT). Am J Cardiol 80:1087-1090, 1997

• 2) Pitt B, Byington RP, Furberg CD et al:Effects of amlodipine on the progression of atherosclerosis and the occurrence of clinical Events. Circulation 102:1503-1510, 2000
  pubmed

P.209 掲載の参考文献

• 1) Blankenberg S, Luc G, Ducimetiere P et al:Inter-leukin-18 and the risk of coronary heart disease in European men:The prospective epidemiological study of myocardial infarction (PRIME). Circulation 108:2453-2459, 2003

• 2) The PRIME study group:The PRIME study:classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland. QJM 91:667-676, 1998

P.211 掲載の参考文献

• 1) Morice MC, Serruys PW, Sousa JE et al:A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773-1780, 2002
  pubmed

• 2) Moses JW, Leon MB, Popma JJ et al:Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323, 2003

• 3) Regar E, Serruys PW, Bode C et al:Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL):sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 106:1949-1956, 2002
  pubmed

P.213 掲載の参考文献

• 1) Lincoff AM, Bittl JA, Harrington RA et al:Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during Percutaneous coronary intervention. JAMA 289:853-863, 2003
  pubmed

• 2) Weitz JI, Hudoba M, Massel D et al:Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III independent inhibitors. J Clin Invest 86:385-391, 1990
  pubmed

• 3) Lefkovits J, Topol EJ:Direct thrombin inhibitors in cardiovascular medicine. Circulation 90:1522-1536, 1994
  pubmed

P.215 掲載の参考文献

• 1) Baim DS, Wahr D, George B et al:Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 105:1285-1290, 2002
  pubmed

P.217 掲載の参考文献

• 1) Teirstein PS, Massullo V, Jani S et al:Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 336:1697-1703, 1997
  pubmed

• 2) Teirstein PS, Massullo V, Jani S et al:Three-year clinical and angiographic follow-up after intracoronary radiation:results of a randomized clinical trial. Circulation 101:360-365, 2000
  pubmed

P.219 掲載の参考文献

• 1) Schnyder G, Roffi M, Flammer Y et al:Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention:the Swiss Heart study:A randomized controlled trial. JAMA 288:973-979, 2002
  pubmed

• 2) Schnyder G, Roffi M, Pin R et al:Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 345:1593-1600, 2001
  pubmed

• 3) Welch GN, Loscalzo J:Homocysteine and ather-othrombosis. N Engl J Med 338:1042-1050, 1998

P.221 掲載の参考文献

• 1) The TIME Investigators:Trial of invasive versus medical therapy in the elderly (TIME):study protocol and patient outline. Heart Drug 1:144-147, 2001

• 2) The TIME Investigators:Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME):a randomised trial. Lancet 358:951-957, 2001

• 3) Aronow WS:Approach to symptomatic coronary disease in the elderly:TIME to change? Lancet 358:945-946, 2001
  pubmed

• 4) Hulley S, Grady D, Bush T et al:Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605-613, 1998

• 5) Hochman JS, Sleeper LA, Webb JG et al:Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Oc-cluded Coronaries for Cardiogenic Shock. N Engl J Med 341:625-634, 1999

P.223 掲載の参考文献

• 1) Waksman R, Bhargava B, White L et al:Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis. Circulation 101:1895-1898, 2000
  pubmed

高血圧

P.227 掲載の参考文献

• 1) Agodoa LY, Appel L, Bakris GL et al:Effect of ramipril vs amlodipine on renal outcomes in hyper-tensive nephrosclerosis:a randomized controlled trial. JAMA 285:2719-2728, 2001

• 2) Wright JT Jr, Bakris G, Greene T et al:Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease:result from the AASK trial. JAMA 288:2421-2431, 2002
  pubmed

P.229 掲載の参考文献

• 1) Estacio RO, Jeffers BW, Schrier RW et al:The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-652, 1998
  pubmed

• 2) Peterson JC, Klahr S, Massry SG et al:Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123:754-762, 1995
  pubmed

• 3) Bakris GL, Williams M, Dworkin L et al:Preserving renal function in adults with hypertension and diabetes:Aconsensus approach. Am J Kidney Dis 36:646-661, 2000

• 4) Viberti G, Wheeldon NM for the MARVAL Study Investigators:Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 106:672-678, 2002

P.232 掲載の参考文献

• 1) ALLHAT Officiers and Coordinators for the ALLHAT Collaborative Research Group:Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone:the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 283:1967-1975, 2000

• 2) ALLHAT Officiers and Coordinators for the ALLHAT Collaborative Research Group:Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Anti:hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997, 2002
  pubmed

P.233 掲載の参考文献

• 1) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Diuretic versus α-blocker as first-step antihypertensive therapy. Final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hympertension 42:239-246, 2003

• 2) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The anti-hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283:1967-1975, 2000

P.235 掲載の参考文献

• 1) Wing LMH, Reid CM, Ryan P et al:A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. (the Second Australian National Blood Pressure Study) N Engl J Med 348:583-592, 2003

• 2) Dahlof B, Devereux RB, Kjeldsen SE et al:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hyper-tension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002

• 3) ALLHAT officers and coordinators for the ALLHAT collaborative research group:Major out-comes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997, 2002
  pubmed

P.237 掲載の参考文献

• 1) 黒川清:高血圧を伴う腎疾患の長期治療試験結果概要. Ther Res 22:275-282, 2001

• 2) 黒川清:高血圧を伴う腎疾患の長期治療試験結果-ATRD-. 新薬と治療 52:31-33, 2002

P.239 掲載の参考文献

• 1) Mogensen CE, Neldam S, Tikkanen I et al:Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes:the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321:1440-1444, 2000
  pubmed

• 2) Nakao N, Yoshimura A, Morita H et al:Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE):arandomised controlled trial. Lancet 361:117-124, 2003
  pubmed

P.241 掲載の参考文献

• 1) Black HR, Elliott WJ, Grandits G et al:Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289:2073-2082, 2003
  pubmed

• 2) Neal B, MacMahon S, Chapman N:Blood Pressure Lowering Treatment Trialist's Collaboration:Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs:results of prospectively designed over-views of randomised trials. Lancet 356:1955-1964, 2000

• 3) Psaty BM, Rennie D:Stopping medical research to save money:a broken pact with researchers and patients. JAMA 289:2128-2131, 2003

P.243 掲載の参考文献

• 1) Nakao N, Yoshimura A, Morita H et al:Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE):a randomized controlled trial. Lancet 361:117-124, 2003
  pubmed

P.245 掲載の参考文献

• 1) Appel LJ, Moore TJ, Obarzanek E et al:Aclinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 336:1117-1124, 1997

• 2) Sacks FM, Svetkey LP, Vollmer WM et al:Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 344:3-10, 2001

P.246 掲載の参考文献

• 1) Lievre M, Marre M, Chatellier G et al:The non-insulin-dependent diabetes, hypertension, microal-buminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study:design, organization, and patient recruitment. Control Clin Trials 21:383-396, 2000
  pubmed

• 2) Vaur L, Gueret P, Lievre M et al:Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria:observations from DIABHYCAR (type 2 DIABetes, Hypertension, Cardiovascular Events ant Ramipril) study. Diabetes Care 26:855-860, 2003
  pubmed

P.248 掲載の参考文献

• 1) van Jaarsveld BC, Krijnen P, Pieterman H et al:The effect of ballon angioplasty on hypertension in atherosclerotic renal-artery stenosis. N Engl J Med 342:1007-1014, 2000

P.251 掲載の参考文献

• 1) Zanchetti A, Bond MG, Hennig M et al:Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis:principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 106:2422-2427, 2002

P.253 掲載の参考文献

• 1) Wilhelmsen L, Berglund G, Elmfeldt D et al:Beta-blockers versus diuretics in hypertensive man:main results from the HAPPHY trial. J Hypertens 5:561-572, 1987

• 2) Wikstrand J, Warnold I, Tuomilehto J et al:Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study. Hypertension 17:579-588, 1991
  pubmed

P.255 掲載の参考文献

• 1) Yusuf S, Sleight P, Pogue J et al:The Heart Outcomes Prevention Evaluation Study Investigators:Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145-153, 2000
  pubmed

• 2) Staessen JA, Wang JG, Thijs L:Cardiovascular protection and blood pressure reduction:ameta-analysis. Lancet 358:1305-1315, 2001

P.257 掲載の参考文献

• 1) Lewis EJ, Hunsicker LG, Clarke WR et al:Reno-protective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
  pubmed

• 2) Brenner BM, Cooper ME, de Zeeuw D et al:Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
  pubmed

P.259 掲載の参考文献

• 1) Brown MJ, Palmer CR, Castaigne A et al:Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study:Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356:366-372, 2000
  pubmed

• 2) Brown MJ, Castaigne A, Ruilope LM et al:IN-SIGHT:international nifedipine GITS study intervention as a goal in hypertension treatment. J Hum Hypertens 10:S 157-S 160, 1996

P.260 掲載の参考文献

• 1) Mancia G, Brown M, Castaigne A et al:Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 41:431-436, 2003

P.261 掲載の参考文献

• 1) Pepine CJ, Handberg-Thurmond E, Marks RG et al:Rationale and design of the international verapamil SR/trandolapril study (INVEST):an Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol 32:1228-1237, 1998
  pubmed

• 2) Pepine CJ, Handberg EM, Cooper-DeHoff RM et al:Acalcium antagonist vs non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST):a randomized control trial. JAMA 290:2805-2816, 2003

P.263 掲載の参考文献

• 1) Parving HH, Lehnert H, Brochner-Mortensen J et al:The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
  pubmed

P.265 掲載の参考文献

• 1) Yui Y, Sumiyoshi T, Kodama K et al:Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease:the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens 27:181-191, 2004
  pubmed

P.267 掲載の参考文献

• 1) Baba S:The J-MIND Study Group:Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 54:191-201, 2001

P.269 掲載の参考文献

• 1) Dahlof B, Devereux RB, Kjeldsen S et al:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002
  pubmed

• 2) Blood Pressure Lowering Treatment Trialists' Collaboration:Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs:results of prospectively designed over-views of randomised trials. Lancet 355:1955-1964, 2000

• 3) Staessen JA, Wang JG, Thijs L:Cardiovascular protection and blood pressure reduction:a meta-analysis. Lancet 358:1305-1315, 2001
  pubmed

P.271 掲載の参考文献

• 1) Kjeldsen SE, Dahlof B, Devereux RB et al:Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losarttan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 288:1491-1498, 2002
  pubmed

P.272 掲載の参考文献

• 1) Lindholm LH, Ibsen H, Dahlof B et al:Cardiovas cular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:1004-1010, 2002

P.275 掲載の参考文献

• 1) Viberti G, Wheeldon NM:MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators:Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus:a blood pressure-independent effect. Circulation 106:672-678, 2002

P.276 掲載の参考文献

• 1) Heart Outcomes Prevention Evaluation Study Investigators:Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus:results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
  pubmed

P.279 掲載の参考文献

• 1) Hansson L, Hedner T, Lund-Johansen P et al:Randornised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension:the Nordic Diltiazem (NORDIL) study. Lancet 356:359-365, 2000
  pubmed

P.281 掲載の参考文献

• 1) Ogihara T:Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. Am J Hypertens 13:461-467, 2000
  pubmed

P.283 掲載の参考文献

• 1) Schrader J, Luders S, Zuchner C et al:Practice vs ambulatory blood pressure measurement under treatment with ramipril (PLUR Study):a randomised, prospective long-term study to evaluate the benefits of ABPM in patients on antihypertensive treatment. J Hum Hypertens 14:435-440, 2000
  pubmed

• 2) Staessen JA, Byttebier G, Buntinx F et al:Anti-hypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators. JAMA 278:1065-1072, 1997
  pubmed

P.285 掲載の参考文献

• 1) Dahlof B, Pennert K, Hansson L:Reversal of left ventricular hypertrophy in hypertensive patients:a metaanalysis of 109 treatment studies. Am Hypertens 5:95-110, 1992
  pubmed

• 2) Gottidiener JS, Reda DJ, Massie BM et al:Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension:comparison of six antihypertensive agents Circulation 95:2007-2014, 1997

• 3) Devereux RB, Palmieri V, Sharpe N et al:Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based anti-hypertensive treatment regimens on left ventricular hypertrophy and diastoleic filling in hypertension. The prospective randomized enalapril study evaluating regression of ventricular enlargement (PRESERVE) trial. Circulation 104:1248-1254, 2001
  pubmed

P.286 掲載の参考文献

• 1) PROGRESS Collaborative Group:Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033-1041, 2001
  pubmed

• 2) Fransen M, Anderson C, Chalmers J et al:PROGRESS:Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6,105 patients with cerebrovascular disease:a randomized controlled trial. Stroke 34:2333-2338, 2003

• 3) Tzourio C, Anderson C, Chapman N et al:PROGRESS Collaborative Group:Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163:1069-1075, 2003

P.288 掲載の参考文献

• 1) The PROGRESS Collaborative Group:Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163:1069-1075, 2003

P.291 掲載の参考文献

• 1) Brenner BM, Cooper ME, de Zeeuw D et al:Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
  pubmed

P.293 掲載の参考文献

• 1) Lithell H, Hansson L, Skoog I et al:The Study on Cognition and Prognosis in the Elderly (SCOPE):principal results of a randomized double-blind intervention trial. J Hypertens 21:875-886, 2003

• 2) Leys D:Neurological protection provided by candesartan:reviewing the latest study results. Curr Med Res Opin 19:445-448, 2003

P.294 掲載の参考文献

• 1) Malacco E, Gnemmi AE, Romagnoli A et al:Systolic hypertension in the elderly:long-term lacidipine treatment. Objective, protocol, and organization. SHELL Study Group. J Cardiovasc Pharmacol 23 (suppl 5):S 62-S 66, 1994

• 2) Malacco E, Mancia G, Rappelli A et al:Treatment of isolated systolic hypertension:the SHELL study results. Blood Press 12:160-167, 2003
  pubmed

P.297 掲載の参考文献

• 1) Hansson L, Lindholm LH, Ekbom T et al:Randomised trial of old and new antihypertensive drugs in elderly patients:cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:1751-1756, 1999
  pubmed

P.298 掲載の参考文献

• 1) Lindholm LH, Anderson H, Ekbom T et al:Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hyper tension-2:a 5-year, prospective, randomised, controlled trial. Lancet 358:539-544, 2001

P.299 掲載の参考文献

• 1) Lindholm LH, Hansson L, Ekbom T et al:Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients:results from the Swedish Trial in Old Patients with Hypertension-2. J Hypertens 18:1671-1675, 2000
  pubmed

• 2) UK Prospective Diabetes Study Group:Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39. BMJ 317:713-721, 1998
  Medical*Online

P.301 掲載の参考文献

• 1) Celis H, Staessen JA, Buntinx F et al:Antihypertensive treatment based on home or office blood pressure measurement:protocol of the randomized controlled THOP trial. Blood. Press Monit 3 (suppl 1):S 29-S35, 1998

• 2) Hond ED, Celis H, Fagard R et al:Self-measured versus ambulatory blood pressure in the diagnosis of hypertension. J Hypertens 21:717-722, 2003
  pubmed

• 3) Staessen JA, Elly Den Hond, Hilde Celis et al:Antihypertensive treatment based on blood pressure measurement at home or in the physician's office. JAMA 291:955-964, 2004

P.303 掲載の参考文献

• 1) http://www.dtu.ox.ac.uk/index.html?maindoc=/ukpds/

P.306 掲載の参考文献

• 1) Julius S, Kjeldsen SE, Brunner H et al:VALUE Trial:Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 16:544-548, 2003
  pubmed

• 2) Julius S, Kjeldsen SE, Weber M et al:Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trial. Lancet 363:2022-2031, 2004

• 3) Weber M, Julius S, Kjeldsen SE et al:Blood pressure dependent and independent effects of anti-hypertensive treatment on clinical events in the VALUE Trial. Lancet 363:2049-2051, 2004
  pubmed

P.309 掲載の参考文献

• 1) Rosei EA, Dal Palu C, Leonetti G et al on behalf of the VHAS Investigators:Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. J Hympertens 15:1337-1344, 1997

• 2) Zanchetti A, Rosei EA, Dal Palu C et al on behalf of the VHAS Investigators:The Verapamil in Hypertension and Atherosclerosis Study (VHAS):results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 16:1667-1676, 1998
  pubmed

P.310 掲載の参考文献

• 1) The BENEDICT Group:The Bergamo Nephrologic Diabetes Complications Trial (BENEDICT):design and baseline characteristics. Controlled Clin Trials 24:442-461, 2003

P.311 掲載の参考文献

• 1) 荻原俊男:本邦での大規模臨床試験-(CASE-J) . 日本臨牀 60:2045-2049, 2002
  Medical*Online

P.312 掲載の参考文献

• 1) Brown MJ, Hopper RV, Dickerson C:Coronary prevention and hypertension research clinic. J Hum Hypertens 7:100, 1993

P.313 掲載の参考文献

• 1) Ohkubo T, Imai Y, Tsuji I et al:Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement:apopulation-based observation in Ohasama, Japan. J Hypertens 16:971-975, 1998

• 2) Fujiwara T, Nishimura T, Ohkuko T et al:Rationale and design of HOMED-BP Study:hypertension objective treatment based on measurement by electrical devices of blood pressure study. Blood Press Monit 7:77-82, 2002
  pubmed

P.314 掲載の参考文献

• 1) Hansson L, Hedner T, Dahlof B:Prospective randomized open blinded end-point evaluation (PROBE) Study:a novel design for intervention trials. Blood Press 1:113-119, 1992
  pubmed

• 2) Stamler J, Stamler R, Neaton JD:Blood pressure, systolic and diastolic, and cardiovascular risks. Arch Intern Med 153:598-615, 1993
  pubmed

• 3) Franklin SS, Gustin W 4th, Wong ND et al:Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circzalation 96:308-315, 1997
  pubmed

• 4) Perry HM, Davis BR, Price TR et al:Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA 284:465-471, 2000
  pubmed

P.315 掲載の参考文献

• 1) Callif RM, Holman R:People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance. J Am Coll Cardiol 41 (suppl A):530 A-531 A, 2003

P.316 掲載の参考文献

• 1) Yusuf S:From the HOPE to the ONTARGET and the TRANSCEND studies:Challenges in improving prognosis. Am J Cardiol 89:18 A-26 A, 2002

• 2) Unger T:The ongoing telmisartan alone and in combination with ramipril global endopoint trial program. Am J Cardiol 91 (10 A):28 G-34 G, 2003

P.317 掲載の参考文献

• 1) Stumpe KO, Ludwig M, Heagerty AM et al:Vascular wall thickness in hypertension:the Perindopril Regression of Vascular Thickening European Community Trial:PROTECT. Am J Cardiol 76:50 E-54 E, 1995

脳血管障害

P.321 掲載の参考文献

• 1) Schrader J, Rothemeyer M, Luders S et al:Hypertension and stroke-rationale behind the ACCESS trial. Basic Res Cardiol 93 (Suppl. 2):69-78, 1998

• 2) Schrader J, Luders S, Kulschewski A et al:The ACCESS Study:Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Strofee 34:1699-1703, 2003
  pubmed

P.323 掲載の参考文献

• 1) O'Brien JR, Etherington, MD:How much aspirin? Thronzb Haemost 64:486, 1990
  pubmed

• 2) Taylor DW, Barnett HJ, Haynes RB et al:Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy:a randomised controlled trial. Lancet 353:2179-2184, 1999
  pubmed

P.325 掲載の参考文献

• 1) CAVATAS investigators:Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS):a randomized trial. Lancet 357:1729-1737, 2001

• 2) Spence D, Eliasziw M:Endarterectomy or angioplasty for treatment of carotid stenosis? Lancet 357:1722-1723, 2001
  pubmed

P.327 掲載の参考文献

• 1) Wahlgren NG, Ranasinha KW, Rosolacci T et al:Clomethiazole acute stroke study (CLASS). Results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients. Strolke 30:21-28, 1999
  pubmed

• 2) Bamford J, Sandercock P, Dennis M et al:Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337:1521-1526, 1991
  pubmed

• 3) Wahlgren NG, Diez-Tejedor E, Teitelbaum J et al:Results in 95 hemorrhagic stroke patients included in CLASS, a controlled trial of clomethiazole versus placebo in acute stroke patients. Stroke 31:82-85, 2000

• 4) Lyden P, Jacoby M, Schim J et al:The clomethiazole acute stroke study in tissue-type plasminogen activator-treated stroke (CLASS-T) . Final results. Neurology 57:1199-1205, 2001

• 5) Lyden P, Shuaib A, Ng K et al:Clomethiazole acute stroke study in ischemic stroke (CLASS-1). Final results. Stroke 33:122-128, 2002
  pubmed

P.329 掲載の参考文献

• 1) Hacke W, Kaste M, Fieschi C et al:Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) . JAMA 274:1017-1025, 1995
  pubmed

• 2) Larrue V, von Kummer R, del Zoppo G et al:Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 28:957-960, 1997
  pubmed

• 3) Fiorelli M, Bastianello S, von Kummer R et al:Hemorrhagic transformation within 36 hours of a cerebral infarct. Relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke 30:2280-2284, 1999

• 4) Manefle C, Larrue V, von Kummer R et al:Association of hyperdense middle cerebral artery sign with clinical outcome in patients treated with tissue plasminogen activator. Stroke 30:769-772, 1999

• 5) The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group:Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med 333:1581-1587, 1995

• 6) Hacke W, Bluhmki E, Steiner T et al:Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set. Post hoc analysis of ECASS I. Strolee 29:2073-2075, 1998

P.331 掲載の参考文献

• 1) Hacke W, Kaste M, Fieschi C et al:Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) . Lancet 352:1245-1251, 1998
  pubmed

• 2) Larrue V, von Kummer R, Muller A et al:Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator. A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II) . Stroke 32:438-441, 2001
  pubmed

• 3) Berger C, Fiorelli M, Steiner T et al:Hemorrhagic transformation of ischemic brain tissue. Asymptomatic or symptomatic? Stroke 32:1330-1335, 2001
  pubmed

P.333 掲載の参考文献

• 1) European Carotid Surgery Trialists:Collaborative Group:Randomized trial of endarterectomy for recently symptomatic carotid stenosis:final results of MRC European Carotid Surgery Trial (ECST). Lancet 351:1379-1387, 1998

• 2) North American Symptomatic Carotid Endarterectomy Trial Collaborators:Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 325:445-453, 1991
  pubmed

P.336 掲載の参考文献

• 1) ESPS Group:European Stroke Prevention Study. Strolee 21:1122-1130, 1990

• 2) Diener HC, Cunha L, Forbes C et al:European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143:1-13, 1996
  pubmed

• 3) Antithrombotic Trailists Collaboration:Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMI 324:71-86, 2002

• 4) Antiplatelet Trailists' Collaboration:Collaborative overview of randomised trials of antiplatelet therapy-I:Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81-106, 1994
  pubmed

P.339 掲載の参考文献

• 1) International Stroke Trial Collaborative Group:The International Stroke Trial (IST):a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischemic stroke. Lancet 349:1569-1581, 1997

• 2) CAST (Chinese Acute Stroke Trial) Collaborative Group:CAST;Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349:1641-1649, 1997

• 3) Antithrombotic Trailists' Collaboration:Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86, 2002
  pubmed

P.341 掲載の参考文献

• 1) The Japanese E 5510 TIA Study-1 (JETS-1) Group, Maruyama S, Uchiyama S, Tohgi H et al:A randomized trial of E 5510 versus aspirin in patients with transient ischemic attacks. Angiology 46:999-1008, 1995
  pubmed

• 2) 池田康夫:新規抗血小板剤E5510の薬理作用. 日本臨牀 50:366-371, 1992
  Medical*Online

P.343 掲載の参考文献

• 1) The Multicenter Acute Stroke Tria1-Europe Study Group:Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 335:145-150, 1996

• 2) Multicentre Acute Stroke Trial. Italy (MAST-1) Group:Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 346:1509-1514, 1995
  pubmed

• 3) Donnan GA, Davis SM, Chambers BR et al:Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 276:961-966, 1996
  pubmed

• 4) The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group:Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587, 1995

P.345 掲載の参考文献

• 1) North American Symptomatic Carotid Endarterectomy Trial Collaborators:Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 325:445-453, 1991
  pubmed

• 2) Barnett HJ, Taylor DW, Eliasziw M et al:Benefit of carotid endarterectomy in patients with symptomatic moderate stenosis. N Engl J Med 339:1415-1425, 1998
  pubmed

• 3) Alamowitch S, Eliasziw M, Algra A et al:Risk, causes, and prevention of ischaemic stroke in elderly patients with symptomatic internal-carotid-artery stenosis. Lancet 357:1154-1160, 2001
  pubmed

P.349 掲載の参考文献

• 1) The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group:Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587, 1995

• 2) The NINDS t-PA Stroke Study Group:Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Strofee 28:2109-2118, 1997

• 3) NINDS;The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group:Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. Stroke 31:2912-2919, 2000

• 4) Hacke W, Donnan G, Fieschi C et al:Association of outcome with early stroke treatment:pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363:768-774, 2004
  pubmed

• 5) Grotta JC, Chiu D, Lu M et al:Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. Stroke 30:1528-1553, 1999
  pubmed

• 6) Broderick JP, Lu M, Kothari R et al:Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke 31:2335-2341, 2000
  pubmed

• 7) Lyden PD, Lu M, Levine SR et al:A modified National Institutes of Health Stroke Scale for use in stroke clinical trials:preliminary reliability and validity. Stroke 32:1310-1317, 2001
  pubmed

P.351 掲載の参考文献

• 1) Silagy CA, MaNeil JJ, Donnan GA et al:The PACE pilot study:12-month results and implications for future primary prevention trials in the elderly. J Am Geriatr Soc 42:643-647, 1994

P.353 掲載の参考文献

• 1) The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group:A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 42:857-865, 1997

• 2) Antiplatelet Trialists' Collaboration:Collaborative overview of randomized trials of antiplatelet therapy I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308:81-106, 1994

• 3) Antithrombotic Trialists' Collaboration:Collaborative meta-analysis of randomized trilas of anti-platelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 324:71-86, 2002

• 4) 篠原幸人, 吉本高志, 福内靖男ほか:脳卒中合同ガイドライン委員会:脳卒中治療ガイドライン2004, 協和企画発行, 2004

• 5) Smith P, Arnesen H, Holme I:The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 323:147-152, 1990
  pubmed

• 6) Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group:Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 343:499-503, 1994

• 7) Mohr Jp, Thompson JL, Lazar RM et al:A comparison of Warfarin and aspirin for prevention of recurrent ischemic stroke. N Engl J Med 345:1444-1451, 2001
  pubmed

P.357 掲載の参考文献

• 1) The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators:Low molecular weight heparinoid ORG 10172 (danaparoid), and outcome after acute ischemic stroke:a randomized controlled trial. JAMA 279:1265-1272, 1998
  pubmed

• 2) International Stroke Trial Collaborative Group, The International Stroke Trial (IST):Arandomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349:1569-1581, 1997
  pubmed

• 3) CAST (Chinese Acute Stroke Trial) Collaborative Group:CAST:randomised placebo-controlled trial of early aspirin use in 20000 patients with acute ischaemic stroke. Lancet 349:1641-1649, 1997

• 4) 田崎義昭, 小林祥泰, 東儀英夫ほか:脳血栓症に対する抗トロンビン薬MD-805の臨床的有用性. プラセボを対照とした多施設二重盲検群間比較試験. 医学のあゆみ 161:887-907, 1992

P.359 掲載の参考文献

• 1) Mohr Jp, Thompson JL, Lazar RM et al:A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345:1444-1451, 2001
  pubmed

• 2) Hankey GJ:Warfarin-Aspirin Recurrent Stroke Study (WARSS) trial;Is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke? Stroke 33:1723-1726, 2002
  pubmed

P.361 掲載の参考文献

• 1) De Schryver EL, on behalf of the European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) Group:Design of ESPRIT;An international randomized trial for secondary pre-vention after non-disabling cerebral ischaemia of arterial origin. Cerebrovasc Dis 10:147-150, 2000

• 2) De Schryver EL, on behalf of the European/Aus-tralian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) Group:ESPRIT;protocol change. Cerebrovasc Dis 11:286, 2001

高脂血症・動脈硬化

P.365 掲載の参考文献

• 1) Egan DA, Garg R, Wilt TJ et al:Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. Am J Cardiol 83:569-575, 1999
  pubmed

• 2) Pettinger MB, Waclawiw MA, Davis KB et al:Compliance to multiple interventions in a high risk Population. Ann Epidemiol 9:408-418, 1999

• 3) Garg R, Elam MB, Crouse JR III et al:Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. Am Heart J 140:792-803, 2000

• 4) Elam MB, Hunninghake DB, Davis KB et al:Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease:the ADMIT study:a randomized trial. JAMA 284:1263-1270, 2000
  pubmed

• 5) Chesney CM, Elam MB, Herd JA et al:Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial(ADMIT). Am Heart J 140:631-636, 2000

• 6) Brown BG, Zhao XQ, Chait A et al:Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583-1592, 2001

P.369 掲載の参考文献

• 1) Downs JR, Clearfield M, Weis S et al:Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels;results of AFCAPS/TexCAPS. JAMA 279:1615-1622, 1998
  pubmed

• 2) Gotto AM Jr, Whitney E, Stein EA et al:Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101:477-484, 2000
  pubmed

• 3) Shepherd J, Cobbe SM, Ford I et al:Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307, 1995
  pubmed

• 4) The Kyushu Lipid Intervention Study Group:A coronary primary intervention study of Japanese men:study design, implementation and baseline data. J Atheroscler Thromb 3:95-104, 1996

• 5) The Kyushu Lipid Intervention Study Group:Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolmia:the Kyushu Lipid Intervention Study. J Atheroscler Thromb 7:110-121, 2000

P.371 掲載の参考文献

• 1) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial(ALLHAT-LLT). JAMA 288:2998-3007, 2002

• 2) Pasternak RC:The ALLHAT lipid lowering trialless is less. JAMA 288:3042-3044, 2002
  pubmed

P.373 掲載の参考文献

• 1) Taylor AJ, Kent SM, Flaherty PJ et al:ARBITER:Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol:arandomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106:2055-2060, 2002

• 2) Shah PK:Low-density lipoprotein lowering and atherosclerosis progression:does more mean less? Circulation 106:2039-2040, 2002
  pubmed

P.375 掲載の参考文献

• 1) Smilde TJ, Trip MD, Wollersheim H et al:Rationale, design and baseline characteristics of a clinical trial comparing the effect of robust vs conventional cholesterol lowering and intima media thickness in patients with familial hypercholesterolemia:the atorvastatin vs simvastatin on atherosclerosis progression (ASAP) study. Clin Drug Invest 20:67-79, 2000

• 2) Smilde TJ, van Wissen S, Wollersheim H et al:Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP):a prospective, randomised, double-blind trial. Lancet 357:577-581, 2001

P.377 掲載の参考文献

• 1) Sever PS, Dahlof B, Poulter NR et al:Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 19:1139-1147, 2001

• 2) Sever PS, Dahlof B, Poulter NR et al:Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):a multicentre randomized controlled trial. Lancet 361:1149-1158, 2003

P.379 掲載の参考文献

• 1) Hedblad B, Wilkstrand J, Janzon L et al:Lowdose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness:Main results from the β-blocker cholesterol-lowering asymptomatic plaque study. Circulation 103:1721-1726, 2001

• 2) Hjalmarson A, Goldstein S, Fagerberg B et al:Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure:the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 283:1295-1302, 2000
  pubmed

P.381 掲載の参考文献

• 1) Tanne D, Benderly M, Goldbourt U et al:Aprospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study. Am J Med 111:457-463, 2001

• 2) The BIP study group:Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease:the Bezafibrate Infarction Prevention (BIP) study. Circulation 102:21-27, 2000

• 3) Adams HP Jr, Bendixen BH, Kappelle LJ et al:Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical tria. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35-41, 1993

P.383 掲載の参考文献

• 1) The ENCORE Investigators:Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease;the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 107:422-428, 2003
  pubmed

P.385 掲載の参考文献

• 1) 武谷雄二, 大内尉義 (編):改訂高齢女性の健康増進のためのホルモン補充療法ガイドライン. メディカルレビュー社, 東京, 2004

• 2) Hulley S, Grady D, Bush T et al:Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613, 1998
  pubmed

P.387 掲載の参考文献

• 1) Hulley S, Grady D, Bush T et al:Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613, 1998
  pubmed

• 2) Grady D, Herrington D, Bittner V et al:Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA 288:49-57, 2002
  pubmed

• 3) 佐久間一郎, 北畠顕:第100回日本内科学会講演会シンポジウム. 1. ホルモンと長寿. 2) 女性の閉経と心血管疾患. 日本内科学会雑誌92:1690-1694, 2003

P.389 掲載の参考文献

• 1) Serruys PW, Feyter P, Macaya C et al:Lescol Intervention Prevention Study (LIPS) Investigators:Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention:a randomized controlled trial. JAMA 287:3215-3222, 2002
  pubmed

• 2) Herd JA, Ballantyne CM, Farmer JA et al:Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study[LCAS]). Am J Cardiol 80:278-286, 1997
  pubmed

• 3) Serruys PW, Foley DP, Jackson G et al:A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty;final results of the flurastatin angiographic restenosis (FLARE) trial. Eur Heart J 20:58-69, 1999

P.391 掲載の参考文献

• 1) Simpson RJ Jr:Placing PRINCE in perspective. JAMA 286:91-93, 2001
  pubmed

• 2) Albert MA, Danielson E, Rifai N et al:Effect of statin therapy on C-reactive protein levels:the pravastatin inflammation/CRP evaluation (PRINCE):a randomized trial and cohort study. JAMA 286:64-70, 2001

• 3) Albert MA, Staggers J, Chew P et al:The pravastatin inflammation CRP evaluation (PRINCE):rationale and design. Am Heart J 141:893-898, 2001
  pubmed

P.393 掲載の参考文献

• 1) Rubins HB, Robins SJ, Collins D et al:Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341:410-418, 1999
  pubmed

• 2) Robins SJ, Collins D, Wittes JT et al:Relation of gemfibrozil treatment and lipid levels with major coronary events:VA-HIT:a randomized controlled trial. JAMA 285:1585-1591, 2001
  pubmed

• 3) Robins SJ:Targeting low high-density lipoprotein cholesterol for therapy:lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial. Am J Cardiol 88 (suppl):19 N-23 N, 2001

P.396 掲載の参考文献

• 1) http://www.nhlbi.nih.gov/whi

• 2) http://www.nhlbi.nih.gov/whi/estro_alone.htm

• 3) http://www.nhlbi.nih.gov/whi/estro_pro.htm

• 4) The Women's Health Initiative Steering Committee:Effects of conjugated equine estrogen in postmenopausal women with hysterectomy the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712, 2004

• 5) http://www.nhlbi.nih.gov/new/press/04-04-13.htm

• 6) http://www.wfubmc.edu/whims/

• 7) http://www.fda.gov/cder/drug/infopage/estrogens_progestins/default.htm

• 8) Writing Group for the Women's Health Initiative Investigators:Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002

P.399 掲載の参考文献

• 1) Merz CN, Kelsey SF, Pepine CJ et al:The Women's Ischemia Syndrome Evaluation (WISE) study:protocol design, methodology and feasibility report. J Am Coll Cardiol 33:1453-1461, 1999
  pubmed

• 2) Sharaf BL, Pepine CJ, Kerensky RA et al:Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation[WISE]Study Angiographic Core Laboratory). Am J Cardiol 87:937-941, 2001
  pubmed

• 3) Lin L, Lewis JF, Kerensky RA et al:Exercise treadmill testing in women with suspected myocardial ischemia;new findings using ACIP protocol;NHLBI Women's Ischemia Syndrome Evaluation (WISE). J Am Coll Cardiol 33:327 A, 1999

• 4) Lewis JF, Lin L, McGorray S et al:Dobutamine stress echocardiography in women with chest pain. Pilot phase data from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). J Am Coll Cardiol 33:1462-1468, 1999

• 5) Reis SE, Holubkov R, Conrad Smith AJ et al:Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease:results from the NHLBI WISE study. Am Heart J 141:735-741, 2001
  pubmed

• 6) Bairey Merz CN, Johnson BD, Sharaf BL et al:Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women:a report from the NHLBI-sponsored WISE study. J Am Coll Cardiol 41:413-419, 2003
  pubmed

• 7) Bairey Merz CN, Olson MB, Johnson BD et al:Cholesterol-lowering medication, cholesterol level, and reproductive hormones in women:the Women's Ischemia Syndrome Evaluation (WISE). Am J Med 113:723-727, 2002

• 8) Rutledge T, Reis SE, Olson M et al:History of anxiety disorders is associated with a decreased likelihood of angiographic coronary artery disease in women with chest pain:the WISE study. J Am Coll Cardiol 37:780-785, 2001
  pubmed